However, preclinical and clinical studies on the effectiveness of IL-6 targeting agents for breast cancer are limited despite the substantial body of evidence indicating that high levels of IL-6 contribute to the poor prognosis and promotion of breast cancer. The gene discussed is IL6; the disease is breast cancer.